Anavex Life Sciences Corp. (AVXL) Given a $15.00 Price Target at Maxim Group

Maxim Group set a $15.00 price target on Anavex Life Sciences Corp. (NASDAQ:AVXL) in a research note issued to investors on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently issued reports on AVXL. Noble Financial reiterated a buy rating on shares of Anavex Life Sciences Corp. in a research report on Sunday, April 9th. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a hold rating to a buy rating and set a $7.00 target price for the company in a research report on Wednesday, April 12th. Finally, ValuEngine downgraded Anavex Life Sciences Corp. from a hold rating to a sell rating in a research report on Friday, June 30th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Anavex Life Sciences Corp. has a consensus rating of Buy and a consensus target price of $11.94.

Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 3.5660% during trading on Monday, reaching $3.7995. 347,195 shares of the company’s stock traded hands. The company has a 50-day moving average of $5.12 and a 200 day moving average of $5.47. Anavex Life Sciences Corp. has a 12 month low of $2.43 and a 12 month high of $6.64. The stock’s market capitalization is $157.21 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, equities research analysts expect that Anavex Life Sciences Corp. will post ($0.37) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/08/08/anavex-life-sciences-corp-avxl-given-a-15-00-price-target-at-maxim-group.html.

A number of institutional investors have recently modified their holdings of the company. American International Group Inc. boosted its stake in shares of Anavex Life Sciences Corp. by 7.1% in the first quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 1,329 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Anavex Life Sciences Corp. by 12.9% in the first quarter. Bank of America Corp DE now owns 39,981 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 4,561 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Anavex Life Sciences Corp. by 14.8% in the second quarter. Rhumbline Advisers now owns 40,342 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 5,205 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Anavex Life Sciences Corp. by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 111,880 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 5,826 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in shares of Anavex Life Sciences Corp. during the first quarter valued at $105,000. 22.88% of the stock is owned by institutional investors and hedge funds.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply